Publications by authors named "C Giannarelli"

Article Synopsis
  • Immune checkpoint inhibitor (ICI) therapies used in cancer treatment may elevate the risk of heart-related issues in cancer survivors by worsening atherosclerosis, a condition affecting artery health.
  • Researchers have identified a network of immune cell interactions within atherosclerotic plaques that can be targeted by ICIs, where a specific group of dendritic cells plays a significant role in immune signaling.
  • The study also indicates that factors like type 2 diabetes and lipid-lowering medications can alter how immune cells interact, potentially affecting plaque inflammation and highlighting the need for strategies to reduce heart disease risk in patients undergoing ICI treatments.
View Article and Find Full Text PDF

Atherosclerosis is fueled by a failure to resolve lipid-driven inflammation within the vasculature that drives plaque formation. Therapeutic approaches to reverse atherosclerotic inflammation are needed to address the rising global burden of cardiovascular disease (CVD). Recently, metabolites have gained attention for their immunomodulatory properties, including itaconate, which is generated from the tricarboxylic acid-intermediate cis-aconitate by the enzyme Immune Responsive Gene 1 (IRG1/ACOD1).

View Article and Find Full Text PDF

Genetic and experimental evidence suggests that Alzheimer's disease (AD) risk alleles and genes may influence disease susceptibility by altering the transcriptional and cellular responses of macrophages, including microglia, to damage of lipid-rich tissues like the brain. Recently, sc/nRNA sequencing studies identified similar transcriptional activation states in subpopulations of macrophages in aging and degenerating brains and in other diseased lipid-rich tissues. We collectively refer to these subpopulations of microglia and peripheral macrophages as DLAMs.

View Article and Find Full Text PDF